Pharmacokinetic analysis of carboplatin and etoposide in a small cell lung cancer patient undergoing hemodialysis

Ken Takezawa, Isamu Okamoto, Masahiro Fukuoka, Kazuhiko Nakagawa

研究成果: ジャーナルへの寄稿記事

13 引用 (Scopus)

抄録

Cancer chemotherapy is not well established for patients on hemodialysis (HD). A 77-year-old man on HD presented with small cell lung cancer. He was treated with the combination of carboplatin and etoposide while the pharmacokinetics of the drugs were monitored. The patient showed a response with manageable toxicity and remained progression free for at least 8 months. The area under the concentration-time curve for each antitumor agent in the patient was within the therapeutic range achieved in individuals with normal renal function. Carboplatin and etoposide chemotherapy combined with HD thus allowed the drugs to achieve an appropriate area under the concentration-time curve and sufficient efficacy in a small cell lung cancer patient with chronic renal failure.

元の言語英語
ページ(範囲)1073-1075
ページ数3
ジャーナルJournal of Thoracic Oncology
3
発行部数9
DOI
出版物ステータス出版済み - 1 1 2008
外部発表Yes

Fingerprint

Carboplatin
Small Cell Lung Carcinoma
Etoposide
Renal Dialysis
Pharmacokinetics
Drug Therapy
Pharmaceutical Preparations
Antineoplastic Agents
Chronic Kidney Failure
Kidney
Neoplasms
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine

これを引用

Pharmacokinetic analysis of carboplatin and etoposide in a small cell lung cancer patient undergoing hemodialysis. / Takezawa, Ken; Okamoto, Isamu; Fukuoka, Masahiro; Nakagawa, Kazuhiko.

:: Journal of Thoracic Oncology, 巻 3, 番号 9, 01.01.2008, p. 1073-1075.

研究成果: ジャーナルへの寄稿記事

@article{d4b77877b93a46f297532f1e8076cf7e,
title = "Pharmacokinetic analysis of carboplatin and etoposide in a small cell lung cancer patient undergoing hemodialysis",
abstract = "Cancer chemotherapy is not well established for patients on hemodialysis (HD). A 77-year-old man on HD presented with small cell lung cancer. He was treated with the combination of carboplatin and etoposide while the pharmacokinetics of the drugs were monitored. The patient showed a response with manageable toxicity and remained progression free for at least 8 months. The area under the concentration-time curve for each antitumor agent in the patient was within the therapeutic range achieved in individuals with normal renal function. Carboplatin and etoposide chemotherapy combined with HD thus allowed the drugs to achieve an appropriate area under the concentration-time curve and sufficient efficacy in a small cell lung cancer patient with chronic renal failure.",
author = "Ken Takezawa and Isamu Okamoto and Masahiro Fukuoka and Kazuhiko Nakagawa",
year = "2008",
month = "1",
day = "1",
doi = "10.1097/JTO.0b013e318183af89",
language = "English",
volume = "3",
pages = "1073--1075",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "9",

}

TY - JOUR

T1 - Pharmacokinetic analysis of carboplatin and etoposide in a small cell lung cancer patient undergoing hemodialysis

AU - Takezawa, Ken

AU - Okamoto, Isamu

AU - Fukuoka, Masahiro

AU - Nakagawa, Kazuhiko

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Cancer chemotherapy is not well established for patients on hemodialysis (HD). A 77-year-old man on HD presented with small cell lung cancer. He was treated with the combination of carboplatin and etoposide while the pharmacokinetics of the drugs were monitored. The patient showed a response with manageable toxicity and remained progression free for at least 8 months. The area under the concentration-time curve for each antitumor agent in the patient was within the therapeutic range achieved in individuals with normal renal function. Carboplatin and etoposide chemotherapy combined with HD thus allowed the drugs to achieve an appropriate area under the concentration-time curve and sufficient efficacy in a small cell lung cancer patient with chronic renal failure.

AB - Cancer chemotherapy is not well established for patients on hemodialysis (HD). A 77-year-old man on HD presented with small cell lung cancer. He was treated with the combination of carboplatin and etoposide while the pharmacokinetics of the drugs were monitored. The patient showed a response with manageable toxicity and remained progression free for at least 8 months. The area under the concentration-time curve for each antitumor agent in the patient was within the therapeutic range achieved in individuals with normal renal function. Carboplatin and etoposide chemotherapy combined with HD thus allowed the drugs to achieve an appropriate area under the concentration-time curve and sufficient efficacy in a small cell lung cancer patient with chronic renal failure.

UR - http://www.scopus.com/inward/record.url?scp=58149113324&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149113324&partnerID=8YFLogxK

U2 - 10.1097/JTO.0b013e318183af89

DO - 10.1097/JTO.0b013e318183af89

M3 - Article

C2 - 18758316

AN - SCOPUS:58149113324

VL - 3

SP - 1073

EP - 1075

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 9

ER -